Oregon Public Employees Retirement Fund’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$654K Hold
26,428
0.01% 1071
2025
Q4
$617K Buy
26,428
+472
+2% +$10.5K 0.01% 1081
2025
Q3
$511K Sell
25,956
-100
-0.4% -$2.06K 0.01% 1135
2025
Q2
$565K Buy
26,056
+417
+2% +$9.84K 0.01% 1064
2025
Q1
$622K Sell
25,639
-705
-3% -$15.9K 0.01% 1015
2024
Q4
$550K Buy
26,344
+100
+0.4% +$2.15K 0.01% 1110
2024
Q3
$522K Sell
26,244
-1,000
-4% -$18.5K 0.01% 1137
2024
Q2
$422K Sell
27,244
-2,700
-9% -$42K 0.01% 1185
2024
Q1
$477K Buy
29,944
+600
+2% +$9.04K 0.01% 1171
2023
Q4
$493K Sell
29,344
-415
-1% -$5.67K 0.01% 1212
2023
Q3
$348K Sell
29,759
-600
-2% -$8.03K ﹤0.01% 1413
2023
Q2
$408K Sell
30,359
-400
-1% -$5.76K ﹤0.01% 1387
2023
Q1
$510K Sell
30,759
-1,080
-3% -$17.8K 0.01% 1284
2022
Q4
$592K Buy
31,839
+211
+0.7% +$3.25K 0.01% 1230
2022
Q3
$406K Buy
+31,628
New +$375K 0.01% 1342

Other funds holding CPRX

Oregon Public Employees Retirement Fund's CPRX Position: Q1 2026 in Review

Oregon Public Employees Retirement Fund held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 26,428 shares worth $654K. The position accounts for 0.01% of the portfolio, ranked #1071.

Oregon Public Employees Retirement Fund first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Oregon Public Employees Retirement Fund held 26,428 shares of Catalyst Pharmaceutical worth $654K as of Q1 2026.
  • Oregon Public Employees Retirement Fund left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up 0.01% of Oregon Public Employees Retirement Fund's portfolio in Q1 2026, its #1071 holding.
  • Oregon Public Employees Retirement Fund first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Oregon Public Employees Retirement Fund's 13F filing for Q1 2026, filed 29 Apr 2026.